---
title: "OpenAI Researcher Miles Wang Is in Talks to Start a $2 Billion AI Drug Startup"
description: "Miles Wang, an OpenAI researcher focused on using AI for scientific discovery, is reportedly in early talks to raise around $200 million at a $2 billion valuation for a new drug-discovery startup. The round is not closed, and Wang has disputed the reported figures, but the story captures how fast money and talent are flowing into AI-for-biology."
category: "Tech"
category_url: https://boursel.com/category/tech
author: "Rafael Ortiz"
published: 2026-07-15T01:24:00.000Z
updated: 2026-07-15T01:24:00.000Z
canonical: https://boursel.com/article/openai-researcher-miles-wang-is-in-talks-to-start-a-2-billion-ai-drug-startup
tags: ["artificial-intelligence", "startups", "drug-discovery", "venture-capital"]
---
# OpenAI Researcher Miles Wang Is in Talks to Start a $2 Billion AI Drug Startup

Miles Wang, an OpenAI researcher focused on using AI for scientific discovery, is reportedly in early talks to raise around $200 million at a $2 billion valuation for a new drug-discovery startup. The round is not closed, and Wang has disputed the reported figures, but the story captures how fast money and talent are flowing into AI-for-biology.

Another senior artificial-intelligence researcher is reportedly stepping out on their own. Miles Wang, who works at OpenAI on using AI to speed up scientific and biological research, is in talks to launch a drug-discovery startup, [with discussions centered on raising about $200 million at a roughly $2 billion valuation, according to TechCrunch](https://techcrunch.com/2026/07/14/openai-researcher-miles-wang-in-talks-to-launch-ai-drug-discovery-startup-valued-at-2b/). The report comes with important caveats, and Wang himself has pushed back on the numbers.

## What is reported, and what is not settled

The key facts are preliminary. [TechCrunch reported that the venture-capital firm Lightspeed Venture Partners is in discussions to lead the round, that several other OpenAI researchers are expected to join, and that the company would build AI models for drug discovery, possibly focused on finding new uses for existing medicines and drugs that previously failed in clinical trials](https://techcrunch.com/2026/07/14/openai-researcher-miles-wang-in-talks-to-launch-ai-drug-discovery-startup-valued-at-2b/). But the same report is explicit that talks are ongoing and could change, and that Wang disputed the reported funding size and description without offering alternative figures. Nothing here is a closed deal.

We flag that clearly because the gap between "in talks" and "done" is where a lot of startup stories quietly fall apart. The verifiable core is narrow: a well-credentialed AI researcher is raising money for an AI-and-biology company, at a valuation being discussed in the billions.

## The strategy: reuse, don't reinvent

The reported focus is worth explaining, because it is a pragmatic one. Discovering a brand-new drug from scratch takes many years and vast sums, and most candidates fail. Looking instead for new uses of drugs that have already cleared safety testing, an approach known as drug repurposing, can be faster and cheaper, since the hardest safety hurdles are already behind them. Pointing AI at that problem, sifting existing compounds and failed trials for overlooked possibilities, is a way to aim for revenue sooner than a from-scratch discovery effort.

## Why investors are leaning in

The talks fit a broader rush of capital into AI-driven drug discovery. Alphabet's Isomorphic Labs and the startup Chai Discovery have both raised large rounds recently as investors bet that AI can improve the odds in a notoriously hit-or-miss business, and as big drugmakers show more willingness to license AI-designed molecules. A new company founded by OpenAI researchers would land squarely in that enthusiasm.

It also fits a pattern on the talent side. Over the past year, senior researchers have peeled away from the largest AI labs to start their own ventures, often attracting outsized valuations on the strength of their pedigree and a thesis rather than a finished product. That dynamic can fund genuine breakthroughs; it can also inflate expectations well ahead of results.

## The bottom line

For now, this is a reported early-stage financing, not a launch, and its headline numbers are contested by the person at the center of it. What is not in doubt is the direction of travel: AI applied to biology is one of the areas where investors are most willing to write large checks, and where the field's most sought-after researchers increasingly want to build. Boursel will report the terms if and when a round actually closes.

## Sources

- [OpenAI researcher Miles Wang in talks to launch AI drug-discovery startup valued at $2B](https://techcrunch.com/2026/07/14/openai-researcher-miles-wang-in-talks-to-launch-ai-drug-discovery-startup-valued-at-2b/)